* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Genetics Chapter 13 p258
Deoxyribozyme wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Human genetic variation wikipedia , lookup
Tay–Sachs disease wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Population genetics wikipedia , lookup
Genetic engineering wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Designer baby wikipedia , lookup
Frameshift mutation wikipedia , lookup
Medical genetics wikipedia , lookup
History of genetic engineering wikipedia , lookup
Point mutation wikipedia , lookup
Genome (book) wikipedia , lookup
DNA paternity testing wikipedia , lookup
Genealogical DNA test wikipedia , lookup
Newborn screening wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Microevolution wikipedia , lookup
Genetic testing wikipedia , lookup
Fetal origins hypothesis wikipedia , lookup
Chapter 13 – Genetic Testing and Gene Therapy (pages 258-273 ONLY) Genetic testing is defined as analysis of chromosomes, DNA, RNA, proteins, or other analytes to detect abnormalities that can cause a genetic disease. 1. Population Screening for Genetic Disease a. Designed to detect treatable disease early i. Pap smears, hypercholesterolemia b. Population screening is large scale testing for disease to see who probably has or doesn’t have a test i. First step to identify a subset of the population, follow up with more tests to confirm diagnosis c. Genetic screening – population screening for gene that causes disease i. Newborn screening ii. Heterozygote detection – e.g. for Tay-Sachs GOAL OF SCREENING: Early recognition of disorder so intervention can prevent/reverse disease process (aka: Newborn metabolism errors) or to make informed reproductive decisions (heterozygous carriers/recessive mutations). General test first, followed by specific diagnostic test. d. Principles of Screening i. Should be serious and relatively common condition 1. PKU – inexpensive test a. Importance of tests validity (sensitivity and specificity) i. Sensitivity – detection of positive ii. Specificity – detection of negative 1. These are reciprocally related (if sensitivity increases, specificity decreases and vice versa) b. Predictive values for a positive or negative test are just the specific population (affected/those who tested positive) i. Refer to Table 13-1 and a/a+b c. CAH – Congenital Adrenal Hyperplasia i. Deficiency of 21-hydroxylase ii. Test is highly accurate The main point: As prevalence of a disease increases, the value of the positive screening test also increases with more true positive tests. (More validity of the test) e. Newborn screening for inborn errors of metabolism (PKU, galactosemia) i. Sickle cell testing, Duchenne Muscular Dystrophy ii. Screening useful for public health in treatable disorders iii. Tandem mass spectrometry has increased the number of detectable diseases f. Heterozygote Screening i. Scanning people who are at risk already ii. Example : Tay-Sachs 1. Autosomal recessive lysosomal storage disorder a. Beta-hexoamninidase A is deficient b. Ganglioside builds up in neuronal lysosomes c. Causes blindness, seizures, hypotonia d. Ashkenazi Jews predisposed iii. Beta Thalassemia 1. Mediterranean and South Asians at risk Heterozygote screening constists of testing (at the phenotype or genotype level) a target population to identify unaffected carriers of a disease gene. The carriers are then given info about risk and reproduction options. g. Presymptomatic diagnosis i. Can help with reproductive decisions ii. Can help with detecting issues early 1. E.g. Breast cancer mutation patients get early mammograms 2. RET mutations thyroidectomy 3. APC and HNPCC h. Psychosocial implication of genetic screening and diagnosis i. Weighing anxiety, cost, and potential stigmatization ii. The issue of accurate testing with possibly increasing healthcare costs. iii. Some autosomal dominant issues can help with survival but many genetic issues are too variable in other “disease causing genes” 2. Molecular Tools for screening and Diagnosis a. Linkage Analysis i. Marking loci in a family to follow specific mutations/alleles ii. Need multiple samples in a family and recomibination and uninformative mating make this difficult b. Direct Mutation Analysis i. Can be used to directly analyze a mutation if it affects a restriction site c. Allele-Specific Oligonucleotides i. Hybridizing a persons DNA with allele-specific oligonucleodtide. ii. Useful if the DNA sequence is known and if the number of disease mutations is limited d. Other methods of direct diagnosis i. Mass spectrometry 1. Detects differences in PCR-amplified DNA ii. Tandem mass spectrometry 1. Used more for newborns, especially protein variations that characterize newborn disorders 3. Prenatal Diagnosis of Genetic Disorders and Congenital Defects a. 15 weeks, alpha-fetoprotein i. Positive test indicates further testing needed for aneuploidy, NTDs ii. Subsequent amniocentesis needed b. Amniocentesis i. Around 15-17 weeks ii. Amniocytes withdrawn, cultured for 7 days, and most results available by day 12 post-test 1. FISH can be done quickly (1-2 days) and give quick aneuploidy result iii. Can suggest NTD 1. NTD may be causing elevated AFP because of underestimated gestational age, fetal death, twins, blood contamination, malformations (omphalocele or gastroschisis) iv. Rate of fetal loss because of this procedure is about 1/200 above background risk level. Can be performed earlier but increases risk c. Chorionic Villus Sampling i. Can be done at 10-11 weeks, better to detect earlier ii. Confined placental mosaicism (1-2% of time) 1. May show a problem in vili that’s not actually wrong with fetus a. Can be confirmed if it is an actual fetal problem with follow up amnio about a month later iii. If performed before 10 weeks, some evidence that may affect fetal limbs d. Other methods of fetal tissue sampling i. Cordocentesis (Percutaneous umbilical blood sampling, PUBS) 1. After 16th week 2. Three application of PUBS a. Cytogenic analysis of blood b. Hematological diseases (immunological) c. True vs. false mosaicism e. Ultra sonography i. Non-invasive, used in conjunction with invasive tests like amnio, and CVS f. Maternal serum screening in 1st and 2nd trimesters i. Link between elevated maternal serum AFP and NTDs ii. Around 15-17 weeks iii. Issue lies with sensitivity and specificity 1. Can increase sensitivity for detecting Downs with Quadruple Screen g. Preimplantation Genetic diagnosis i. During in-vitro fertilization, few cells removed from blastomere, and amplified with PCR to detect early genetic issues ii. PCR may cause inaccuracies iii. Polar Body Diagnosis (the inactivated meiotic divided cell) 1. Can test its DNA to check for disease mutations 2. Can’t test paternal DNA with this h. Fetal DNA in maternal circulation i. Isolating fetal DNA from maternal blood, low risk ii. But difficult to isolate, unknown accuracy 4. Fetal Treatment a. Treatment of inborn errors and hormone deficiencies i. Biotin responsive carboxylase deficiency 1. Treated with oral biotin – resulted in healthy newborn ii. CAH 1. Treated at 10 weeks with oral dexamethasone iii. Surgical approaches are moderately successful 1. Success in myelomeningocele (to restore CSF flow)